To verify the promotion effect of Pyk2 on glioma cell invasion after anti-VEGF treatment in vivo, tumor cell invasiveness surrounding the tumor rim in rat C6 intracranial xenograft was evaluated by vimentin staining [27] after bevacizumab treatment with or without Pyk2 inhibition. The gene discussed is VIM; the disease is central nervous system cancer.